These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 25004214)

  • 1. Sanofi's dengue vaccine first to complete phase 3.
    Sinha G
    Nat Biotechnol; 2014 Jul; 32(7):605-6. PubMed ID: 25004214
    [No Abstract]   [Full Text] [Related]  

  • 2. Sanofi’s successful Phase 3 trials may lead to first-ever dengue vaccine in 2015.
    Hum Vaccin Immunother; 2014; 10(12):3427. PubMed ID: 25864560
    [No Abstract]   [Full Text] [Related]  

  • 3. Sanofi's dengue vaccine rounds final corner.
    Mullard A
    Nat Rev Drug Discov; 2014 Nov; 13(11):801-2. PubMed ID: 25359368
    [No Abstract]   [Full Text] [Related]  

  • 4. Dengue vaccines for travelers: has the time come?
    Wilder-Smith A
    J Travel Med; 2015; 22(3):200-2. PubMed ID: 25827475
    [No Abstract]   [Full Text] [Related]  

  • 5. New chapter unfolding in the fight against dengue with an unwritten ending.
    Thiry G; Hombach J; Constenla D; Carvalho A; Durbin A
    Trans R Soc Trop Med Hyg; 2014 Oct; 108(10):597-8. PubMed ID: 25217182
    [No Abstract]   [Full Text] [Related]  

  • 6. The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection.
    Pitisuttithum P; Bouckenooghe A
    Expert Rev Vaccines; 2016 Jul; 15(7):795-8. PubMed ID: 27171845
    [No Abstract]   [Full Text] [Related]  

  • 7. The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries.
    Aguiar M; Stollenwerk N; Halstead SB
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005179. PubMed ID: 28002420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dengue vaccine roll-out: getting ahead of the game.
    Zorlu G; Fleck F
    Bull World Health Organ; 2011 Jul; 89(7):476-7. PubMed ID: 21734760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue.
    Azevedo AS; Gonçalves AJ; Archer M; Freire MS; Galler R; Alves AM
    PLoS One; 2013; 8(3):e58357. PubMed ID: 23472186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine.
    Imoto J; Konishi E
    Vaccine; 2007 Jan; 25(6):1076-84. PubMed ID: 17084490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Status of vaccine research and development of vaccines for dengue.
    Vannice KS; Durbin A; Hombach J
    Vaccine; 2016 Jun; 34(26):2934-2938. PubMed ID: 26973072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addendum to report of the Global Advisory Committee on Vaccine Safety (GACVS), 10-11 June 2015¹. Safety of CYD-TDV dengue vaccine.
    Wkly Epidemiol Rec; 2015 Aug; 90(34):421-3. PubMed ID: 26298882
    [No Abstract]   [Full Text] [Related]  

  • 13. A recombinant live attenuated tetravalent vaccine for the prevention of dengue.
    Guy B; Noriega F; Ochiai RL; L'azou M; Delore V; Skipetrova A; Verdier F; Coudeville L; Savarino S; Jackson N
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28590795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defeating dengue: a challenge for a vaccine.
    Nat Med; 2012 Nov; 18(11):1622-3. PubMed ID: 23135514
    [No Abstract]   [Full Text] [Related]  

  • 15. Exploring the role of a recently licensed dengue vaccine in Australian travellers.
    Thevarajan I; Torresi J; Simmons C
    Med J Aust; 2020 Feb; 212(3):102-103.e1. PubMed ID: 31909484
    [No Abstract]   [Full Text] [Related]  

  • 16. [Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico's Universal Vaccination Program].
    Hernández-Ávila M; Lazcano-Ponce E; Hernández-Ávila JE; Alpuche-Aranda CM; Rodríguez-López MH; García-García L; Madrid-Marina V; López Gatell-Ramírez H; Lanz-Mendoza H; Martínez-Barnetche J; Díaz-Ortega JL; Ángeles-Llerenas A; Barrientos-Gutiérrez T; Bautista-Arredondo S; Santos-Preciado JI
    Salud Publica Mex; 2016; 58(1):71-83. PubMed ID: 26879510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
    Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
    Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAGE committee advice on dengue vaccine.
    Pang T
    Lancet Infect Dis; 2016 Aug; 16(8):880-2. PubMed ID: 27477966
    [No Abstract]   [Full Text] [Related]  

  • 19. Sanofi Pasteur shows efficacy of its dengue vaccine in phase 3.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(6):1427. PubMed ID: 25264688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dengue vaccine development: a 75% solution?
    Halstead SB
    Lancet; 2012 Nov; 380(9853):1535-6. PubMed ID: 22975339
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.